- Home
- EWCZ vs GALT Comparison
EWCZ vs GALT Comparison
Compare EWCZ & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWCZ
- GALT
- Stock Information
- Founded
- EWCZ 2004
- GALT 2000
- Country
- EWCZ United States
- GALT United States
- Employees
- EWCZ N/A
- GALT N/A
- Industry
- EWCZ Package Goods/Cosmetics
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- EWCZ Consumer Discretionary
- GALT Health Care
- Exchange
- EWCZ Nasdaq
- GALT Nasdaq
- Market Cap
- EWCZ 239.2M
- GALT 232.3M
- IPO Year
- EWCZ 2021
- GALT N/A
- Fundamental
- Price
- EWCZ $4.77
- GALT $4.10
- Analyst Decision
- EWCZ Buy
- GALT Strong Buy
- Analyst Count
- EWCZ 7
- GALT 3
- Target Price
- EWCZ $5.86
- GALT $6.00
- AVG Volume (30 Days)
- EWCZ 512.8K
- GALT 291.4K
- Earning Date
- EWCZ 08-13-2025
- GALT 08-14-2025
- Dividend Yield
- EWCZ N/A
- GALT N/A
- EPS Growth
- EWCZ N/A
- GALT N/A
- EPS
- EWCZ 0.20
- GALT N/A
- Revenue
- EWCZ $212,509,000.00
- GALT N/A
- Revenue This Year
- EWCZ N/A
- GALT N/A
- Revenue Next Year
- EWCZ $2.17
- GALT N/A
- P/E Ratio
- EWCZ $24.00
- GALT N/A
- Revenue Growth
- EWCZ N/A
- GALT N/A
- 52 Week Low
- EWCZ $2.72
- GALT $0.73
- 52 Week High
- EWCZ $8.91
- GALT $4.41
- Technical
- Relative Strength Index (RSI)
- EWCZ 51.92
- GALT 66.50
- Support Level
- EWCZ $4.29
- GALT $3.50
- Resistance Level
- EWCZ $4.82
- GALT $4.20
- Average True Range (ATR)
- EWCZ 0.28
- GALT 0.31
- MACD
- EWCZ 0.06
- GALT -0.03
- Stochastic Oscillator
- EWCZ 66.51
- GALT 65.93
About EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax. Its services include Brazilian Waxing, Brow Waxing, Body Waxing, Facial Waxing, All Waxing Services, Eyebrow Tinting, Laser Hair Removal, Men's Waxing Services and others.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.